TNFα blockade prevents the development of inflammatory bowel disease in HLA-B27 transgenic rats

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 1, 2009, Pages 164-176

  Milia, Anna Franca ^a   Manetti, Mirko ^a   Generini, Sergio ^a   Polidori, Lucia ^a   Benelli, Gemma ^a   Cinelli, Marina ^a   Messerini, Luca ^a   Ibba Manneschi, Lidia ^a   Matucci Cerinic, Marco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Apoptosis; Fas Fas L; HLA B27 transgenic rats; IBD; TNF

Indexed keywords

ANIMALIA; RATTUS;

CYTOKINE; FAS ANTIGEN; FAS LIGAND; HLA B27 ANTIGEN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL; APOPTOSIS; ARTICLE; BLOOD; COLON; CYTOLOGY; DRUG ANTAGONISM; ENTERITIS; FISCHER 344 RAT; GENETICS; HUMAN; IMMUNOLOGY; MALE; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; RAT; SPONDYLARTHRITIS; TRANSGENIC RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; APOPTOSIS; COLON; CYTOKINES; FAS LIGAND PROTEIN; HLA-B27 ANTIGEN; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; RANDOM ALLOCATION; RATS; RATS, INBRED F344; RATS, TRANSGENIC; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SPONDYLARTHRITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58849105550     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00310.x     Document Type: Article

References (40)

1. De Keyser F, Van den Bosch F, Mielants H. Anti-TNFα therapy in ankylosing spondylitis. Cytokine. 2006 33 : 294 8.
2. Jacques P, Mielants H, Coppieters K, De Vos M, Elewaut D. The intimate relationship between gut and joint in spondyloarthropathies. Curr Opin Rheumatol. 2007 19 : 353 7
3. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2 m: an animal model of HLA-B27-associated human disorders. Cell. 1990 63 : 1099 112.
4. Tran TM, Dorris ML, Satumtira N, Richardson JA, Hammer R, Shang J, Taurog JD. Additional human b2- microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27 transgenic rats. Arthritis Rheum. 2006 54 : 1317 27.
5. Breban M. Animal models and in vitro models for the study of aetiopathogenesis of spondyloarthropathies. Clin Rheumatol. 1998 12 : 611 26.
6. Breban M, Hacquard-Bouder C, Falgarone G. Animal model of HLA-B27 associated disease. Curr Mol Med. 2004 4 : 31 40.
7. Faure M. The chronic colitis developed by HLA-B27 transgenic rats is associated with altered in vivo mucin synthesis. Dig Dis Sci. 2004 49 : 339 46.
8. Taurog JD, Maika SD, Simmons WA, Breban M, Hammert RE. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J Immunol. 1993 150 : 4168 78.
9. Hacquard-Bouder C, Falgarone G, Bosquet A, Smaoui F, Monnet D, Ittah M, Breban M. Defective costimulatory function is a striking feature of antigen-presenting cells in an HLA-B27-transgenic rat model of spondyloarthropathy. Arthritis Rheum. 2004 50 : 1624 35.
10. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998 392 : 245 52.
11. Hacquard-Bouder C, Ittah M, Breban M. Animal models of HLA-B27-associated diseases: new outcomes. Joint Bone Spine. 2006 73 : 132 8.
12. Taurog JD, Maika SD, Satumtira N, Dorris ML, McLean IL, Yanagisawa H, Sayad A, Stagg AJ, Fox GM, Lê O'Brien A, Rehman M, Zhou M, Weiner AL, Splawski JB, Richardson JA, Hammer RE. Inflammatory disease in HLA-B27 transgenic rats. Immunol Rev. 1999 169 : 209 23.
13. van Lieshout AW, Barrera P, Smeets RL, Pesman GJ, van Riel PL, van den Berg WB, Radstake TR. Inhibition of TNF alpha during maturation of dendritic cells results in the development of semi-mature cells: a potential mechanism for the beneficial effects of TNF alpha blockade in rheumatoid arthritis. Ann Rheum Dis. 2005 64 : 408 14.
14. Bertrand V, Quéré S, Guimbaud R, Sogni P, Chauvelot-Moachon L, Tulliez M, Lamarque D, Charreire J, Giroud JP, Couturier D, Chaussade S, Breban M. Effects of murine recombinant interleukin- 10 on the inflammatory disease of rats transgenic for HLA-B27 and human beta 2- microglobulin. Eur Cytokines Netw. 1998 9 : 161 70.
15. Braun J, Baraliakos X, Listing J, Davis J, Van der Heijde D, Haibel H. Differences in the incidence of flares or new onset of inflammatory bowel disease in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 2007 57 : 639 47.
16. Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Maruyama Y, Matsushita I, Iwaoka Y, Saniabadi A. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol. 2004 99 : 1532 8.
17. Pinkoski MJ, Green DR. Apoptosis in the Regulation of Immune Responses. J Rheumatol. 2005 32 : 19 25.
18. Boatright KM, Renatus M, Scott FL, Sperandio S, Shin H, Pedersen IM, Ricci JE, Edris WA, Sutherlin DP, Green DR, Salvesen GS. A unified model for apical caspase activation. Mol Cell. 2003 1 : 529 41.
19. Bonfoco E, Stuart PM, Brunner T, Lin T, Griffith TS, Gao Y, Nakajima H, Henkart PA, Ferguson TA, Green DR. Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. Immunity. 1998 9 : 711 20.
20. Pinkoski MJ, Droin NM, Green DR. Tumor necrosis factor alpha up-regulates nonlymphoid Fas-ligand following superantigen- induced peripheral lymphocyte activation. J Biol Chem. 2002 277 : 42380 5.
21. Pinkoski MJ, Droin NM, Lin T, Genestier L, Ferguson TA, Green DR. Nonlymphoid Fas ligand in peptide-induced peripheral lymphocyte deletion. Proc Natl Acad Sci USA. 2002 99 : 16174 9.
22. Keith JC Jr., Sainz IM, Isordia-Salas I, Pixley RA, Leathurby Y, Albert LM, Colman RW. A monoclonal antibody against kininogen reduces inflammation in the HLA-B27 transgenic rat. Arthritis Res Ther. 2005 7 : R769 76.
23. Peterson RL, Wang L, Albert L, Keith JC Jr., Dorner AJ. Molecular effects of recombinant human interleukin-11 in the HLAB27 rat model of inflammatory bowel disease. Lab Invest. 1998 78 : 1503 12.
24. Bamias G, Nyce MR, De La Rue SA, Cominelli F. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med. 2005 143 : 895 904.
25. Makino J, Andoh A, Hata K, Yotsuya S, Shikama H, Imamura M, Fujiyama Y, Bamba T. Inhibitory effects of the new anti-inflammatory agent, IS-741, on spontaneous colitis in HLA-B27(β2- microglobulin transgenic rats. J Gastroenterol Hepatol. 2002 17 : 854 60.
26. Harnish DC, Albert LM, Leathurby Y, Eckert AM, Ciarletta A, Kasaian M, Keith JC Jr. Beneficial effects of estrogen treatment in the HLA-B27 transgenic rat model of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2004 286 : G118 25.
27. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998 115 : 182 205.
28. Tidball CS. The nature of the intestinal epithelial barrier. Am J Dig Dis. 1971 16 : 745 67.
29. Podolsky DK. Regulation of intestinal epithelial proliferation: a few answers, many questions. Am J Physiol. 1993 264 : G179 86.
30. Liu Z, Jiu J, Liu S, Fa X, Li F, Du Y. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion. J Autoimmun. 2007 29 : 187 194.
31. Dieleman LA, Hoentjen F, Qian BF, Sprengers D, Tjwa E, Torres MF, Torrice CD, Sartor RB, Tonkonogy SL. Reduced ratio of protective versus proinflammatory cytokine responses to commensal bacteria in HLA-B27 transgenic rats. Clin Exp Immunol. 2004 136 : 30 9.
32. Dieleman LA, Goerres MS, Arends A, Sprengers D, Torrice C, Hoentjen F, Grenther WB, Sartor RB. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut. 2003 52 : 370 6.
33. Green DR, Ferguson TA. The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol. 2001 2 : 917 24.
34. Ferguson TA, Green DR, Griffith TS. Cell death and immune privilege. Int Rev Immunol. 2002 21 : 153 72.
35. Marini M, Bamias G, Rivera-Nieves J, Moskaluk CA, Hoang SB, Ross WG, Pizarro TT, Cominelli F. TNFα neutralization ameliorates the severity of murine Crohn's-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc Natl Acad Sci USA. 2003 100 : 8367 71.
36. Corredor J, Yan F, Shen CC, Tong W, John SK, Wilson G, Whitehead R, Polk DB. Tumor necrosis factor regulates intestinal epithelial cell migration by receptor-dependent mechanisms. Am J Physiol Cell Physiol. 2003 284 : C953 61.
37. Ueyama H, Kiyohara T, Sawada N, Isozaki K, Kitamura S, Kondo S, Miyagawa J, Kanayama S, Shinomura Y, Ishikawa H, Ohtani T, Nezu R, Nagata S, Matsuzawa Y. High Fas ligand expression on lymphocytes in lesions of ulcerative colitis. Gut. 1998 43 : 48 55.
38. Boone DL, Dassopoulos T, Chai S, Chien M, Lodolce J, Ma A. Fas is not essential for lamina propria T lymphocytes homeostasis. Am J Physiol Gastrointest Liver Physiol. 2003 285 : G382 8.
39. Van den Brande JM, Koehler TC, Zelinkova Z, Bennink RJ, te Velde AA, ten Cate FJ, van Deventer SJ, Peppelenbosch MP, Hommes DW. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut. 2007 56 : 509 17.
40. Mizoguchi E, Mizoguchi A, Takedatsu H, Cario E, de Jong YP, Ooi CJ, Xavier RJ, Terhorst C, Podolsky DK, Bhan AK. Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology. 2002 122 : 134 44.